May 10, 2012
-- New York, NY – American Conference Institute (ACI) has announced the return of the San Diego edition of its Hatch-Waxman Boot Camp, now in its third year. The event will feature a “Who’s Who” of the West Coast’s Biopharma IP and Regulatory Bar. This unique program, which takes place on June 25-26, 2012, at the Hilton San Diego Resort and Spa in San Diego, CA, has been designed to give counsel and advisors to brand name and generic drug companies --- and biopharmas --- critical insights into commercialization and the pre-approval process, and also provide you an in-depth review of Hatch-Waxman and other IP basics relative to small molecules and biologics.
An all-star faculty of West Coast IP and regulatory counsel
--- all having a wealth of experience through working for brand names and generics as well as biopharmas will help you to understand the interplay of IP and FDA regulation relative to pharma/biotech patents vis-à-vis Hatch-Waxman and recently released biosimilars guidance and ensure that you are aware of the intersection of the newly promulgated America Invents Act with Hatch-Waxman.
“2011 brought the enactment of the America Invents Act and 2012 marked the release of the FDA Draft Guidance on Biosimilars. It is now essential to understand how this will impact the Hatch-Waxman arena,” said Leigh Leventhal, Director of Legal Programs at ACI. “The Hatch-Waxman Boot Camp – San Diego Edition has become the gathering place of the Southern California life sciences IP Bar, and we are thrilled with the expert faculty who have come together for this year’s event.”
More information about this event, including a full agenda, faculty list, and brochure can be accessed at http://www.americanconference.com/HWBootCamp